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Purpose. To evaluate the midterm oncologic results of extraperitoneal laparoscopic radical prostatectomy (EPLRP) for Asian men
with localized prostate cancer. Methods. Between 2004 and 2009, 218 men underwent EPLRP at an Asian tertiary hospital. The
meanpreoperativeprostate-speciﬁcantigen(PSA)was15.5ng/mlandmeanGleasonscorewas6.6.StagedistributionswerecT1a-b
in21cases,cT1cin139,cT2in48andcT3in10.DiseaserecurrencewasdeﬁnedasPSA≥0.2ng/mLin2consecutivemeasurements
or initiation of secondary therapy. Results. Postoperative pathological stage was pT2a-b in 33 patients, pT2cN0 in 10, pT3a in 27,
pT3b in 36, pT4 in 9 and pN1 in 10. Positive surgical margins occurred in 14.6% and 48.6% for pT2 and pT3 diseases, respectively
(P<. 001). The overall PSA recurrence-free survival at 3 and 5 years was 82.1% and 74.5%. By the pathological stages, 3-year
recurrence-free survival was 92.4% (pT2), 81.1% (pT3a), 62.6% (pT3b-4) and 55.6% (pN1), respectively (P<. 001). Conclusions.
EPLRP is curative even for some locally advanced prostate cancers in a midterm follow-up. Even at an Asian center of low volume
of radical prostatectomy EPLRP still provides oncologic outcomes similar to that of high volume centers.
1.Introduction
The incidence and mortality rate of prostate cancer in Tai-
wan, although not as high as those in the Western countries,
were increasing signiﬁcantly during the past decade [1].
The eﬃcacy of various treatment modalities, especially for
the potentially curable clinically localized prostate cancer,
needs to be monitored carefully to ensure that the patients
receive the best treatment available [2, 3]. Open retropubic
radical prostatectomy (RRP) has been widely accepted for
thetreatmentofchoiceforclinicallylocalizedprostatecancer
since it is generally well tolerated with low morbidity and
oﬀers satisfactory oncologic and functional outcomes [4,
5]. For a minimally invasive approach to be accepted as
a reasonable alternative to RRP, it must provide at least
equivalent midterm oncologic and functional results and
demonstrate relatively lower perioperative and long-term
morbidities [6].
Laparoscopic radical prostatectomy (LRP) was ﬁrst pio-
neered in 1992 by Schuessler et al. [7]. In 1997, they
published the initial series of nine cases and concluded
that LRP was feasible but not eﬃcacious in comparison
to the conventional counterpart [8]. However, after the
modiﬁcations and standardization of the LRP technique by
Guillonneau and Vallancien [9, 10] and Abbou et al. [11]i n
1999, a progressively growing interest for LRP has blossomed
among urologists. Since then, several studies comparing LRP
with RRP have been reported in the literature [12–15].
However, there were limited reports from Taiwan and/or
Asia, an area of relatively low-case volume of radical prosta-
tectomy,toevaluatewhetherthepotentialadvantagesofsuch
a technically demanding operation is really worthwhile.
We performed our ﬁrst LRP in 2002 with a transperi-
toneal Montsouris approach [9] and introduced the
extraperitoneal technique (EPLRP) since 2004 [16]. Until
r e c e n t l y ,w eh a v ec o m p l e t e da l m o s t2 5 0E P L R Pp r o c e d u r e s ,2 Prostate Cancer
and at least 180 cases have been followed up for more than
one year at our institution. Herein, we reviewed the midterm
oncologic outcomes of our EPLRP series and compared the
results with those of other high-volume centers.
2. Methods
2.1. Patient Selection. Between December 2004 and June
2009, 218 consecutive men underwent EPLRP for clinically
localized prostate cancers at National Taiwan University
Hospital, a tertiary referral center. All procedures were
performed by three urologic surgeons (SCC, MKL, and
CYH). Men with concomitant operations other than total
extraperitoneal (TEP) hernia repair were excluded from
analysis.
2.2. Evaluation of Clinical Parameters. The preoperative
clinical parameters including patient’s age, preoperative
prostate-speciﬁc antigen (PSA) level, biopsy Gleason score,
and clinical stages were reviewed. The pathological data
included Gleason score, pathological stages, positive surgical
margin (PSM) rate, and presence of perineural invasion
(PNI). PSM was considered if tumor was present at the
inked margin of the specimen. Pathological staging was done
using the 2002 AJCC TNM system and Gleason scoring
was assigned according to modern convention. Recurrence
of disease was deﬁned as serum PSA value ≥ 0.2ng/mL
in at least two consecutive measurements or initiation of
secondary therapy. Recurrence-free survival was deﬁned
as the time between EPLRP and the ﬁrst PSA increase
(≥0.2ng/mL). Men who had a detectable postoperative PSA
immediately after surgery or received adjuvant treatment
(hormone or radiation) before an increasing postoperative
PSA were assumed to have experienced failure at the time
of surgery (i.e., recurrence-free survival = 0 month). After
EPLRP, all men except 13 received regular PSA monitoring
and digital rectal examination (DRE) at our clinics every
3 months for the ﬁrst 2 years and then every 6 months
thereafter.
2.3. Surgical Procedures. To create the extraperitoneal work-
ing space for EPLRP procedure, we developed a novel
technique with the assistance of a Visiport Optical Trocar
[16].Afterestablishmentoftheworkingspacewithpneumo-
extraperitoneum, LRP was executed by ﬁrst controlling
the deep dorsal vein complex and then dissecting the
prostate and seminal vesicles by an antegrade approach.
All patients received bilateral pelvic lymph node dissection
(PLND, external iliac, and obturator fossa groups) despite
preoperative risk stratiﬁcation.
2.4. Statistical Analysis. The PSA recurrence-free survival
was analyzed using the Kaplan-Meier method, and the
log-rank test was used to compare survival curves of
various subgroups. Survival curves were further stratiﬁed by
preoperative PSA and pathological characteristics (Gleason
score, pathological stages, PSM, and perineural invasion).
The impact of various preoperative and postoperative risk
Table 1: Clinical patient and pathological characteristics.
No. patients 218
Mean age at surgery (year, range) 64.6 (45–82)
Mean preop. PSA (ng/mL, range) 15.5 (0.26–185)
Preop. PSA (ng/mL)
< 47 ( 3 . 2 % )
4–10 96 (44.0%)
10–20 68 (31.2%)
> 20 47 (21.6%)
Clinical stage (%)
cT1a-b 21 (9.6%)
cT1c 139 (63.8%)
cT2 48 (22.0%)
cT3 10 (4.6%)
Mean biopsy Gleason score (range) 6.6 (3–10)
Biopsy Gleason score (%)
< 7 99 (45.4%)
= 7 93 (42.7%)
> 7 26 (11.9%)
factors on recurrence-free survival was analyzed using Cox
regression analysis. A P value of less than .05 was considered
statistically signiﬁcant. All analyses were performed with
Statistical Package for the Social Science software (SPSS 13th
ed., Chicago, IL, USA).
3. Results
3.1. General Characteristics. Preoperative patient character-
istics are listed in Table 1.
3.2.PathologicalResults(Table 2). Meanprostatevolumewas
43.7gm (range 19 to 112). Pathological stage was pT2a-b in
33 (15.1%), pT2c in 103 (47.2), pT3a in 27 (12.4%), pT3b
in 36 (16.5%), and pT4 in 9 (4.2%). All patients (100%)
underwent bilateral PLND in external iliac and obturator
fossagroups,whichrevealedpositivelymphnodesin10cases
(4.6%). Postoperative Gleason score was <7 in 52 (23.9%), 7
in 145 (66.5%), and >7 in 21 men (9.6%), respectively. PSM
occurred in 27.1% of patients, including 20 of 137 of pT2
(14.6%), 35 of 72 of pT3 (48.6%), and 4 of 9 of pT4 (44.4%)
disease.
3.3. Oncologic Outcomes (Table 2). Thirteen patients have
been lost during followup (5.9%). Seven patients (3.2%) had
neoadjuvant treatment, and a total of 14 patients (6.4%)
received adjuvant therapy before postoperative PSA started
to increase, including external beam radiation alone in 3,
hormone therapy alone in 7, and a combination of external
beam radiation and hormone therapy in 4.
None of the patients died of prostate cancer progression
during the followup period. Three patients died of other
causes, namely, acute myeloid leukemia, acute myocardial
infarction, and sepsis in each one.Prostate Cancer 3
Table 2: Pathological and oncologic outcomes.
Median followup (months) 34 (2–66)
Pathological stage (%)
pT2a-bN0 33 (15.1%)
pT2cN0 103 (47.2%)
pT3aN0 27 (12.4%)
pT3bN0 36 (16.5%)
pT4N0 9 (4.2%)
pT1-4N1 10 (4.6%)
Pathological Gleason sum (%)
< 7 52 (23.9%)
= 7 145 (66.5%)
3+4 87
4+3 58
> 7 21 (9.6%)
Positive surgical margins (%)
Overall 59 (27.1%)
pT2 20 (14.6%)
pT3 35 (48.6%)
pT4 4 (44.4%)
Perineural invasion (%)
Overall 136 (62.4%)
pT2 64 (47.1%)
pT3/4 62 (45.6%)
pN1 10 (7.3%)
PSA recurrence (%)
Overall 25 (13.1%)
pT2 10 (7.3%)
pT3a 4 (14.8%)
pT3b 9 (25.0%)
pT1-4N1 2 (20.0%)
During a median followup of 34 months (range 2 to 66),
PSArecurrenceoccurredin25patients(13.1%),andwewere
only able to determine the location of recurrence in three
patients (2 local and 1 metastatic). Of whom, 21 received
secondary therapy including external beam radiation in 7,
hormone therapy in 7, and a combination of radiation and
hormone therapy in 7. The median time to progression was
31 months, with 33 months for pT2, 32.5 months for pT3a,
22 months for pT3b-4, and 11 months for pT2-4N1 disease.
T h ea c t u a r i a lo v e r a l lP S Ar e c u r r e n c e - f r e es u r v i v a lr a t ea t3
and 5 years was 82.1% and 74.5%, respectively (Figure 1).
Whenstratiﬁedbypathologicalstages,the3-yearrecurrence-
free survival rate was 92.4% for pT2, 81.1% for pT3a, 62.6%
for pT3b-4, and 55.6% for pN1 (P<. 001, Figure 3).
The recurrence-free survival by preoperative PSA strata
is shown in Figure 2. The 3-year recurrence-free survival rate
was87.8%forPSA<10ng/mL,84.3%forPSA10–20ng/mL,
and 71.7% for PSA ≥ 20ng/mL (P = .08).
To study the prognostic value of Gleason score, we
divided the patients into those with Gleason score < 7, score
= 7, and score > 7. The 3-year recurrence-free survival was
83.3% for Gleason score < 7, 79.1% for score = 7, and 59.8%
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Figure 1: PSA recurrence-free survival after EPLRP in Taiwanese
men.
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Figure 2: PSA recurrence-free survival stratiﬁed by preoperative
PSA level.
for score > 7( P = .001, Figure 4). For patients with Gleason
score 7, the 3-year recurrence-free survival was 73.7% and
85.8% for those with predominant grade 4 (i.e., 4 + 3) and
grade 3 (i.e., 3+4) disease, respectively (P = .07).
Men with PSM had a worse PSA recurrence-free survival
rate of 66.8% at 3 years compared with 89.2% for those with
negative surgical margins (P<. 001, Figure 5). Recurrence-
free Kaplan-Meier survival curves also revealed that presence
of perineural invasion was also a signiﬁcant parameter with
regard to outcome (P = .003, Figure 6).
While faily acceptable oncologic outcomes were achieved
in our series, the functional outcomes of our EPLRP series
showed that the percentages of the patients dry (use less than
1pad/day) after surgery were 66% at 3 months after surgery,4 Prostate Cancer
Table 3: Oncologic outcomes of extraperitoneal laparoscopic radical prostatectomy (EPLRP) series.
Rozet et al. [17] Rassweiler et al. [18]P a u l e t a l . [ 19] Stolzenburg et al. [20] Tai et al. [16]
Study period 1998–2004 1999–2004 2000–2007 2001–2008 2004–2009
No. institutions 1 1 1 3 1
No. surgeons 4 — 3 9 3
No. patients 600 500 1115 2400 218
Mean age (yrs) 62 (47–73) 64.0 (43–81) 62.5 (42–81) 63.3 (41–81) 64.6 (45–82)
Median followup (months) 12 40 35.6 — 34
Mean preoperative PSA (ng/mL) 7.4 11.7 (0.08–93) 9.8 (0.8–99) 9.8 (0.08–93) 16.3 (0.7–185)
Pelvic lymph node dissection (%) — 83.4% 41.6% 50.8% 100%
Pathological stage
pT2 72.0% 59.2% 59.5% 70.5% 62.3%
pT3a 19.2% 21.4% 22.4% 19.7% 12.4%
pT3b 8.8% 12.8% 9% 9.4% 16.5%
pT4 — 3.8% 6.9% 0.3% 4.2%
pT1-4N1 — 1.4% 2.2% — 4.6%
Positive surgical margin (%)
Overall 17.7% 19.0% 26.0% 16.0% 27.1%
pT2 14.6% 7.4% 16.1% 8.1% 14.6%
pT3 25.6% 31.8% 34.6% 35.7% 47.9%
PSA recurrence-free survival rate
3-year — 83.0% 84% — 82.1%
5-year — 73.1% 83% — 74.5%
92% at 6 months, and 96% at 18 months. Since not all these
patients were done to preserve their neurovascular bundles
and not all the patients have pre- and postoperative erection
functions scores to be compared, we are not able to provide
the erection functional outcome among this patient cohort.
4. Discussions
Radical prostatectomy is the major curative treatment for
localized prostate cancer, and the open retropubic approach
remains currently the gold standard option for such disease
[21]. Published reports have shown that, in the hands of an
experienced urological surgeon, this procedure is associated
with minimal intraoperative and postoperative morbidity,
without compromising the oncologic and functional out-
comes [22]. Thus, it sets a high standard for the emerging
technique, laparoscopic radical prostatectomy, to be an ideal
alternative.
Several large series have addressed the oncologic eﬀec-
tiveness of LRP, with the PSM rates between 6.2% and 27.5%
for pT2 tumors and between 31.1% and 68.0% for pT3
tumors. The 3-year actuarial recurrence-free survival rates
were between 72% and 95% (between 89% and 98% for
pT2 tumors and between 51% and 79% for pT3 tumors
Table 4: Multivariate Cox proportional hazard model for predic-
tion of PSA recurrence.
HR 95% CI P value
Preoperative PSA level 1.501 1.005, 2.243 .047
Pathological stage 1.543 1.281, 1.860 <.001
Gleason score 2.828 1.564, 5.112 .001
Surgical margin 2.162 1.477, 3.165 <.001
Perineural invasion 3.765 1.460, 9.710 .006
when stratiﬁed by pathological stage) [18, 23–26]. Moreover,
Touijer et al. have even reported a longer oncologic result
with 78% and 71% for overall 5-year and 8-year probability
of freedom from recurrence, respectively [27]. However,
all of these LRP data were predominantly based on the
transperitoneal approach; information regarding the onco-
logic followup of EPLRP was limited (Table 3). Stolzenburg
et al. reported the largest EPLRP series with 2400 cases, and
thePSMratewas8%forpT2and35.6%forpT3cancers[20].
Paul et al. ﬁrst published the midterm results of 1115 EPLRP
procedureswithamedianfollowupof35.6months(range1–
92). The overall PSA recurrence-free survival rates were 84%
at 3 years and 83% at 5 years. According to the pathologicalProstate Cancer 5
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Figure 3: PSA recurrence-free survival stratiﬁed by pathological
stage.
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Figure 4: PSA recurrence-free survival stratiﬁed by Gleason score.
stages, 5-year progression-free survival rate was 93.4% for
pT2 tumors, 70.2% for pT3 tumors, and 42.7% for pT4
tumors. Preoperative PSA, Gleason score, tumor stage, nodal
status, and surgical margins were signiﬁcant independent
predictors of biochemical recurrence-free survival [19].
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Figure 5: PSA recurrence-free survival stratiﬁed by surgical margin
status.
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Figure 6: PSA recurrence-free survival stratiﬁed by the presence of
perineural invasion (PNI).
To our knowledge, the present study was the only series
describing the oncologic results of EPLRP from Asia, an
area of relatively low incidence of prostate cancer and low
volumeofradicalprostatectomy.Comparedtoothercohorts,
patients in the present study seemed to have a higher preop-
erative PSA level and more unfavorable pathological stages
(pT3-pN1) after surgery. However, our ﬁndings still provide
acceptable 3-year and 5-year PSA recurrence-free survival
in 82.1% and 74.5% of patients, respectively. When further
classiﬁed by pathological stages, our EPLRP recurrence-free
survival rate at 3 years was 92.4% for pT2, 81.1% for pT3a,
62.6% for pT3b-4, and 55.6% for pT1-4N1 cancers. The
overall PSM rate was 27.1%, with 14.6% for pT2 and 47.9%6 Prostate Cancer
for pT3 disease. Comparison of pathological and oncologic
outcomes with other published EPLRP series is listed in
Table 3. All these parameters of cancer control rates were
within the conﬁdence ranges reported by other high-volume
centers using either open retropubic or laparoscopic surgery.
Thus, we suggest that, even in an area of low prostate cancer
incidence, LRP performed with extraperitoneal approach
for patients with clinically localized prostate cancer is an
oncologically safe and eﬀective treatment.
Although the case number in the current series was
not enormous, we observed not only comparable oncologic
outcomesforpT2prostatecancerpatientsbutalsoacceptable
3-year oncologic outcomes even for patients with advanced
localized prostate cancer (pT3 and pT4). This coincides with
the recent concept that radical prostatectomy might provide
cure for advanced localized prostate cancer and thus should
beoﬀeredasavaluableandviabletreatmentalternativewhen
consulting such patients preoperatively [28, 29].
In a multivariate Cox model, we found some risk
factors ominous for PSA recurrence-free survival for our
patient population, namely, higher preoperative PSA level,
higherpathological stage(≥pT3), higher Gleason score(>7),
existence of positive surgical margins, or/and perineural
invasion on the pathological analysis (Table 4). These risk
factors were similar to those previously reported in other
series [20, 23–25, 30].
We performed our ﬁrst LRP in 2002 with a transperi-
toneal approach. After initial successful experience in 30
cases, we started to perform the extraperitoneal technique
since 2004 with the original idea of its potential advantage
in preserving peritoneal integrity. This single-institution
EPLRP experience is herein presented to demonstrate that
EPLRP is a satisfactory and viable option in treating patients
with clinically localized prostate cancer.
5. Conclusions
Based on our midterm followup data, EPLRP provided
3- and 5-year PSA recurrence-free survival in 82.1% and
74.5% of patients, respectively. We suggest that, even in an
area of low prostate cancer incidence, LRP performed with
extraperitoneal approach is an oncologically safe and eﬀec-
tive treatment for clinically localized prostate cancer. Long-
term oncologic data are needed to conﬁrm the midterm
results.
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